New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 19, 2012
13:32 EDTAMGNAmgen finalizes $762M agreement to settle federal investigations
Amgen announced it has finalized a settlement agreement with the U.S. government, 49 states and the District of Columbia related to previously disclosed investigations. Amgen will pay approximately $612M to resolve its civil liability related to certain promotional practices related to the drugs Aranesp, EPOGEN, NEUPOGEN, Neulasta, Enbrel and Sensipar as alleged in the unsealed qui tam complaints and $150M to resolve its criminal liability relating to the marketing of Aranesp, and the $762M agreement is covered by a 3Q11 charge. The company also entered into a Corporate Integrity Agreement with the Office of Inspector General of the U.S. Department of Health and Human Services. As part of the agreement, Amgen has pleaded guilty to a single misdemeanor count of misbranding Aranesp by promoting it in a way that was different from the dosages in the label. The plea was entered yesterday in the U.S. District Court for the Eastern District of New York and was accepted today by the same court.
News For AMGN From The Last 14 Days
Check below for free stories on AMGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2014
09:04 EDTAMGNOn The Fly: Pre-market Movers
Subscribe for More Information
07:04 EDTAMGNAmgen price target raised to $138 from $125 at RBC Capital
Subscribe for More Information
06:16 EDTAMGNOptions expected to be active: TWTR BWLD AXP DWA PNRA AMGN X FB
Subscribe for More Information
06:00 EDTAMGNAmgen price target raised to $150 from $143 at Piper Jaffray
Subscribe for More Information
July 29, 2014
18:35 EDTAMGNOn The Fly: After Hours Movers
Subscribe for More Information
16:22 EDTAMGNAmgen says total product sales increased 8% in Q2
Total product sales increased 8% for the second quarter of 2014 versus the second quarter of 2013. The increase was mainly driven by ENBREL, Kyprolis, Prolia and XGEVA. Product sales in the second quarter of 2013 included a positive adjustment of $185M to previous estimates for managed Medicaid rebates based on claims experience.
16:21 EDTAMGNAmgen to reduce global workforce by 12%-15%
The company announced a restructuring plan today to invest in continuing innovation and the launch of its new pipeline molecules, while improving its cost structure. Initial efforts include streamlining the organization, reducing layers of management, increasing managerial spans of responsibility and beginning implementation of a revised geographic site plan. As a first step, the company will reduce staff by 2,400-2,900, beginning later this year and continuing through 2015, predominantly in the U.S. This represents approximately 12% to 15% of Amgen’s global workforce. The company will also close its facilities in the states of Washington and Colorado
16:19 EDTAMGNAmgen raises FY14 EPS view to $8.20-$8.40 from $7.90-$8.20, consensus $8.09
Subscribe for More Information
16:16 EDTAMGNAmgen reports Q2 EPS $2.37, consensus $2.07
Reports Q2 revenue $5.18B, consensus $4.9B.
15:53 EDTAMGNNotable companies reporting after market close
Subscribe for More Information
13:49 EDTAMGNEarnings Preview: Amgen counting on newer drugs to boost sales
Subscribe for More Information
11:11 EDTAMGNAmgen technical comments before results
Subscribe for More Information
July 25, 2014
09:19 EDTAMGNAmgen weekly volatility elevated into Q2 and outlook
Subscribe for More Information
07:36 EDTAMGNEMA adopts positive opinion on new indication for Xgeva
Subscribe for More Information
05:35 EDTAMGNBayer, Onyx reports NEXAVAR Phase 3 trial did not meet primary endpoint
Subscribe for More Information
July 17, 2014
16:10 EDTAMGNAmgen announces positive Phase 3 results for AMG 416
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use